Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by All India Institute of Medical Sciences, New Delhi
Sponsor:
Collaborator:
Dr. Reddy's Laboratories Limited
Information provided by (Responsible Party):
Sameer Bakhshi, All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov Identifier:
NCT01402024
First received: July 19, 2011
Last updated: February 11, 2013
Last verified: February 2013
  Purpose

Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed distressing toxicity of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy use. CINV causes disturbance in daily living of cancer patient and reduces compliance with treatment Even with the standard anti-emetic measures up to 50% patient can suffer from this complication. Whereas there is standard anti-emetic guideline exists in case of adult patients, there no such guidelines made in pediatric population. The new drug Aprepitant has been recommended for use in adults with high efficacy, there no such concrete data available in children regarding its use. There are few retrospective reports and limited data available regarding use of Aprepitant in children with satisfactory efficacy in reducing CINV. As there no randomized large data to suggests its efficacy and its routine use in children, we have planned this study.


Condition Intervention Phase
Chemotherapy Induced Nausea and Vomiting
Drug: Aprepitant
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: A Study to Evaluate the Anti-emetic Effect of Aprepitant Versus Placebo as an Add-on Therapy in Children and Adolescent Receiving Chemotherapy: A Randomized, Doubly Blinded Controlled Trial

Resource links provided by NLM:


Further study details as provided by All India Institute of Medical Sciences, New Delhi:

Primary Outcome Measures:
  • - Numbers of episodes of nausea and vomiting. - Duration of nausea (in hours). - Severity of nausea as per Edmonton's Symptom Assessment System (ESAS), numerical scale for nausea. [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • - Chemotherapy induced additional side effects. - Number of anti-emetic dosage (other than aprepitant) required for treatment of vomiting. [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 220
Study Start Date: August 2011
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aprepitant
It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
Drug: Aprepitant

The patient on study group with weight category of 15-40 kg will receive:

D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and

The patient with weight category of 41-65 kg in study group will receive:

D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg

Other Name: Empov
Placebo Comparator: Control
It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
Drug: Placebo

Patient on control group with weight category of 15-40 kg will receive:

D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and

The patient on control group with weight category of 41-65 kg will receive:

D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).

Other Name: Empov placebo capsules

Detailed Description:

Population:

Children and adolescents (5-18 years) with weight between 15-65 kg receiving highly emetogenic chemotherapy (HEC) -

  • VAC (vincristine, dactinomycin/Adriamycin, cyclophosphamide)
  • ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
  • Cisplatin/Doxorubicin

Sampling technique Subjects who met the eligibility criteria will be randomly assigned using random allocation number generated by computer into one of the two groups. The unit of randomization will be the subject at first cycle of HEC. The same patient will not be enrolled for twice

Procedure for data collection:

  1. The data will be collected from each patient from d1 to d10 of chemotherapy of which patient will received chemotherapy in day care, maximum up to d3.
  2. After taking consent patient will be enrolled as per inclusion and exclusion criteria, and randomized to one of two groups. All baseline assessment will be done. Patient will be explained about the filling of the diary. In first 2 days. The subjects will fill the diary under the investigator supervision, and the rest of filling will be in home. Reinforcement will be done over phone.

Procedure of double blinding

  • Double blinding will be done for the intervention. Four different boxes will be made for capsules. Total 3 capsules for 3 days will be made in a blister pack, mentioning the d1, d2, d3 (for each capsule). Two different body weight groups will be made: 15-40 kg, and 41-65 kg.
  • Group "A" will be the code for Aprepitant group and group "B" will be code for control group. Both patient and the investigator will be blinded regarding medicine in the code.
  Eligibility

Ages Eligible for Study:   5 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All subjects must have a confirmed diagnosis of malignancy and receiving highly emetogenic chemotherapy first time (VAC, ABVD and CDDP/Doxorubicin)
  • Age group 5-18 years with weight between 15-65 kg
  • Children/adolescents and their caregiver who can understand Hindi or English and willing to participate in the study (with written informed consent)

Exclusion Criteria:

  • Significant organ dysfunction
  • Active infection
  • Pregnancy
  • Uncontrolled medical condition other than malignancy
  • Need for contraindicated concomitant medication
  • Patients receiving chemotherapy other than VAC, ABVD and CDDP/Doxorubicin
  • Treatment with another investigational drug within 4 weeks of study start or prior Aprepitant use
  • Had received or will receive RT to abdomen or pelvis in the week prior to treatment
  • Vomited in the 24 hr prior to treatment
  • Prior exposure to highly emetogenic chemotherapeutics
  • Abnormal lab values (ANC<1500/mm3, TLC<3000/mm3, Plt<100,000/mm3, AST/ALT> 2.5 times of ULN, bill>1.5 times of ULN, S.cr>1.5 times of ULN, patient on systemic steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01402024

Contacts
Contact: Sameer Bakhshi, MD 011-26588153 sambakh@hotmail.com
Contact: Atul Sharma, DM 011-26589490 atul1@hotmail.com

Locations
India
Dr. BRA IRCH, AIIMS Recruiting
New Delhi, Delhi, India, 110029
Contact: Sameer Bakhshi, MD    011-26588153    sambakh@hotmail.com   
Principal Investigator: Sameer Bakhshi, MD         
Sub-Investigator: Atul Sharma, DM         
Sponsors and Collaborators
All India Institute of Medical Sciences, New Delhi
Dr. Reddy's Laboratories Limited
Investigators
Principal Investigator: Sameer Bakhshi, MD Dr. BRA IRCH, AIIMS, New Delhi (India)
  More Information

No publications provided

Responsible Party: Sameer Bakhshi, Additional Professor, All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov Identifier: NCT01402024     History of Changes
Other Study ID Numbers: CT/38/011/RS
Study First Received: July 19, 2011
Last Updated: February 11, 2013
Health Authority: India: Indian Council of Medical Research

Additional relevant MeSH terms:
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Antiemetics
Aprepitant
Emetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents

ClinicalTrials.gov processed this record on July 20, 2014